WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
UEFA wants Euro 2024 referees to speak more with captains and get more respect in return
NC State, Baylor headline the field for the 2025 Maui Invitational as it returns to Lahaina
8 watches owned by F1 great Michael Schumacher fetch more than $4 million at auction in Geneva
Alice Munro, Nobel literature winner revered as short story master, dead at 92
Marston's losses narrow amid hopes of summer sporting calendar boost
Not so Cool Britannia! Noel Gallagher gives damning verdict on Keir Starmer
FBI, Homeland Security warn of possible threats to LGBTQ events, including Pride Month activities
Analysis: Larson enters conversation with Verstappen as best drivers in the world
Navy surgeon who operated on 12